JP2015533128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533128A5 JP2015533128A5 JP2015535936A JP2015535936A JP2015533128A5 JP 2015533128 A5 JP2015533128 A5 JP 2015533128A5 JP 2015535936 A JP2015535936 A JP 2015535936A JP 2015535936 A JP2015535936 A JP 2015535936A JP 2015533128 A5 JP2015533128 A5 JP 2015533128A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- disease
- medicament
- manufacture
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 50
- -1 phosphate ester Chemical class 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 150000002772 monosaccharides Chemical class 0.000 claims description 7
- 208000028867 ischemia Diseases 0.000 claims description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 150000008163 sugars Chemical class 0.000 claims description 6
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 4
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 4
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims description 4
- 150000001735 carboxylic acids Chemical class 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 239000000412 dendrimer Substances 0.000 claims description 4
- 229920000736 dendritic polymer Polymers 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229940097043 glucuronic acid Drugs 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 4
- 150000003871 sulfonates Chemical class 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 206010028851 Necrosis Diseases 0.000 claims description 3
- 108091000080 Phosphotransferase Proteins 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 230000017074 necrotic cell death Effects 0.000 claims description 3
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 3
- 102000020233 phosphotransferase Human genes 0.000 claims description 3
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims description 3
- 200000000007 Arterial disease Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- AVGPOAXYRRIZMM-UHFFFAOYSA-N D-Apiose Natural products OCC(O)(CO)C(O)C=O AVGPOAXYRRIZMM-UHFFFAOYSA-N 0.000 claims description 2
- ASNHGEVAWNWCRQ-LJJLCWGRSA-N D-apiofuranose Chemical compound OC[C@@]1(O)COC(O)[C@@H]1O ASNHGEVAWNWCRQ-LJJLCWGRSA-N 0.000 claims description 2
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N D-apiofuranose Natural products OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 claims description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 208000011191 Pulmonary vascular disease Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 208000014139 Retinal vascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 2
- 0 *c(c(*)c1)ccc1C(Oc1c2cccc1)=C(*)C2=O Chemical compound *c(c(*)c1)ccc1C(Oc1c2cccc1)=C(*)C2=O 0.000 description 1
- UTRMWEQAQGGUAY-UHFFFAOYSA-N CN(C(C(C1O)O)O)OC1C(O)=O Chemical compound CN(C(C(C1O)O)O)OC1C(O)=O UTRMWEQAQGGUAY-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012904444 | 2012-10-11 | ||
| AU2012904444A AU2012904444A0 (en) | 2012-10-11 | Novel Flavonoid compounds and uses thereof | |
| PCT/AU2013/001175 WO2014056038A1 (en) | 2012-10-11 | 2013-10-11 | Novel flavonoid compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018121870A Division JP2018184414A (ja) | 2012-10-11 | 2018-06-27 | 新規フラボノイド化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533128A JP2015533128A (ja) | 2015-11-19 |
| JP2015533128A5 true JP2015533128A5 (enExample) | 2016-11-04 |
| JP6567419B2 JP6567419B2 (ja) | 2019-08-28 |
Family
ID=50476785
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535936A Expired - Fee Related JP6567419B2 (ja) | 2012-10-11 | 2013-10-11 | 新規フラボノイド化合物およびその使用 |
| JP2018121870A Withdrawn JP2018184414A (ja) | 2012-10-11 | 2018-06-27 | 新規フラボノイド化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018121870A Withdrawn JP2018184414A (ja) | 2012-10-11 | 2018-06-27 | 新規フラボノイド化合物およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10316053B2 (enExample) |
| EP (1) | EP2906578B8 (enExample) |
| JP (2) | JP6567419B2 (enExample) |
| KR (1) | KR102169002B1 (enExample) |
| CN (2) | CN107759553A (enExample) |
| AU (1) | AU2013330222B2 (enExample) |
| BR (1) | BR112015008156A2 (enExample) |
| CA (1) | CA2887488C (enExample) |
| DK (1) | DK2906578T3 (enExample) |
| ES (1) | ES2730926T3 (enExample) |
| MX (1) | MX368855B (enExample) |
| NZ (1) | NZ707087A (enExample) |
| RU (1) | RU2647842C2 (enExample) |
| SG (1) | SG11201502758SA (enExample) |
| TR (1) | TR201908822T4 (enExample) |
| WO (1) | WO2014056038A1 (enExample) |
| ZA (1) | ZA201502703B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111233806A (zh) * | 2020-03-20 | 2020-06-05 | 武汉轻工大学 | 一种3,5,4＇-三乙酰氧基-7-羟基黄酮的制备方法 |
| CN112168976B (zh) * | 2020-10-15 | 2022-11-04 | 天津科技大学 | 一种黄酮衍生物前药及合成和作为抗肿瘤药物的应用 |
| CN115504970B (zh) * | 2022-10-18 | 2023-04-18 | 黑龙江中医药大学 | 一种用于治疗心肌缺血的黄酮类衍生物及其制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06161129A (ja) * | 1992-11-25 | 1994-06-07 | Mita Ind Co Ltd | 電子写真感光体 |
| US6555523B1 (en) | 1999-07-08 | 2003-04-29 | Patrick T. Prendergast | Use of cirsiliol and derivatives to treat infections |
| AU7561300A (en) * | 1999-09-23 | 2001-04-24 | Universiteit Van Maastricht | Novel flavonoids |
| JP2003019867A (ja) | 2001-04-19 | 2003-01-21 | Mitsubishi Chemicals Corp | 光記録媒体 |
| GB0125532D0 (en) | 2001-10-24 | 2001-12-12 | Burton Michael | Enzyme activity indicators |
| WO2006030322A2 (en) | 2004-09-17 | 2006-03-23 | University Of Manitoba | Use of fla vone/fla vanone derivatives fn the treatment or prevention of respiratory conditions |
| US20060084615A1 (en) * | 2004-10-20 | 2006-04-20 | Chan Albert S | Puerarin derivatives and their medical uses |
| CA2601028C (en) * | 2005-03-11 | 2014-05-27 | Howard Florey Institute Of Experimental Physiology And Medecine | Flavonoid compounds and uses thereof |
| JP2007230145A (ja) | 2006-03-02 | 2007-09-13 | Mitsubishi Chemicals Corp | 光学記録媒体の記録層形成用色素、及びそれを用いた光学記録媒体、その光学記録媒体の記録方法 |
| US7897637B2 (en) | 2006-07-19 | 2011-03-01 | The Salk Institute For Biological Studies | Methods of using flavonoids to enhance memory |
| US7863323B1 (en) * | 2006-10-27 | 2011-01-04 | The University Of Melbourne | Flavonols |
| DE102008012909A1 (de) | 2008-03-06 | 2009-09-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Flavonoidverbindungen für die Prophylaxe und Therapie ischämischer oder entzündlicher Herz- und Kreislauferkrankungen |
| CN101244057B (zh) | 2008-03-11 | 2010-06-02 | 中国人民解放军第二军医大学 | 具有降血脂作用的3-取代氧基-3',4'-二甲氧基黄酮类化合物 |
| JP5424296B2 (ja) | 2008-08-28 | 2014-02-26 | 静岡県公立大学法人 | フラボン誘導体の製造方法およびシアル酸転移酵素阻害剤 |
| EP2424541A2 (en) | 2009-04-27 | 2012-03-07 | Limerick BioPharma, Inc. | Phosphorylated and phosphonated pyrone analogs for therapeutic treatment |
| JP2012044944A (ja) | 2010-08-27 | 2012-03-08 | Railway Technical Research Institute | トルエン検出方法 |
| DE102011104441A1 (de) * | 2011-06-16 | 2012-12-20 | Fujitsu Technology Solutions Intellectual Property Gmbh | Schaltnetzteil, Betriebsverfahren und Verwendung eines Schaltnetzteils in einem Computer |
| JP6122431B2 (ja) * | 2011-08-11 | 2017-04-26 | アーマロン バイオ ピーティーワイ リミテッド | フラボノイド化合物及びその使用方法 |
| CN102631362B (zh) | 2012-01-19 | 2013-04-24 | 中国人民解放军第二军医大学 | 射干异黄酮类化合物在制备预防和治疗紫外线致皮肤损伤药物中的应用 |
| CN102617672B (zh) | 2012-02-24 | 2014-03-12 | 大连大学 | 一种金花茶黄酮苷及其制备方法和用途 |
| CN102697768A (zh) | 2012-06-07 | 2012-10-03 | 中国人民解放军第二军医大学 | 一类木犀草素类似黄酮类化合物在制备抗肿瘤药物中的用途 |
| DK2904403T3 (en) * | 2012-10-02 | 2018-07-16 | Sphingotec Gmbh | PROCEDURE FOR DIAGNOSTICATION OR MONITORING OF Kidney Function or Diagnosis of Kidney Function |
-
2013
- 2013-10-11 WO PCT/AU2013/001175 patent/WO2014056038A1/en not_active Ceased
- 2013-10-11 JP JP2015535936A patent/JP6567419B2/ja not_active Expired - Fee Related
- 2013-10-11 NZ NZ707087A patent/NZ707087A/en not_active IP Right Cessation
- 2013-10-11 KR KR1020157012173A patent/KR102169002B1/ko not_active Expired - Fee Related
- 2013-10-11 CA CA2887488A patent/CA2887488C/en not_active Expired - Fee Related
- 2013-10-11 CN CN201711032323.9A patent/CN107759553A/zh active Pending
- 2013-10-11 BR BR112015008156A patent/BR112015008156A2/pt not_active Application Discontinuation
- 2013-10-11 CN CN201380058798.9A patent/CN104955831A/zh active Pending
- 2013-10-11 ES ES13846070T patent/ES2730926T3/es active Active
- 2013-10-11 US US14/435,164 patent/US10316053B2/en not_active Expired - Fee Related
- 2013-10-11 AU AU2013330222A patent/AU2013330222B2/en not_active Ceased
- 2013-10-11 DK DK13846070.4T patent/DK2906578T3/da active
- 2013-10-11 RU RU2015117641A patent/RU2647842C2/ru active
- 2013-10-11 MX MX2015004578A patent/MX368855B/es active IP Right Grant
- 2013-10-11 SG SG11201502758SA patent/SG11201502758SA/en unknown
- 2013-10-11 EP EP13846070.4A patent/EP2906578B8/en active Active
- 2013-10-11 TR TR2019/08822T patent/TR201908822T4/tr unknown
-
2015
- 2015-04-21 ZA ZA2015/02703A patent/ZA201502703B/en unknown
-
2018
- 2018-06-27 JP JP2018121870A patent/JP2018184414A/ja not_active Withdrawn